Skip to main content
Equibles

YDES · YD Bio Ltd

Track YDES — free

Use YDES with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research YDES.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.11 -1.00 (-12.33%) At close · Oct 5
Rebalance outlook locked
Market Cap
$400.91M
Shares
70.83M
Volume · Oct 5 258.51K Avg daily vol (3M) 354.51K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.11 Open$7.90 Day$6.81–8.03 52W close$1.90–20.09 Avg vol 30d538K Short int43K · 0.1% float · 1.0d Short vol54% DataAug 2025–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+16.9%
Year over year
Operating margin
-883.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.1%
Year over year · more shares
Price change (1Y)
-57.9%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +16%
above
Price vs 50-day avg +81%
above
RSI (14) 66
neutral
MACD trend Positive
52-week position 29%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +101%
trailing
6-month return +25%
trailing
YTD return −42%
this year
Relative strength +13%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow Accumulating
+63% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$128.5K over 90 days · 0% sells
Short interest Rising
0.06% of float · ▲ +223.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
13 holders — near 1-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Weak
Revenue growth +17%
Y/Y
Gross margin 28%
contracting
EPS growth −500%
Y/Y
Free cash flow $-8.0M
Quant / Vol
risk profile
Very High
Volatility 131%
annualized · 1-yr
Max drawdown −91%
past year
ATR 14.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+16% Bullish
Price vs 50-day avg
+81% Bullish
RSI (14)
66 Neutral
MACD trend
Positive Bullish
52-week position
29% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $6 — 200d above 50d
Institutional flow Accumulating
+63% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$128.5K over 90 days · 0% sells
Short interest Rising
0.06% of float · ▲ +223.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
13 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $7 · 29% Range high $20
vs 200-day avg +16% vs 50-day avg +81%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
YDES
YD Bio Ltd
this stock
$400.91M -41.7% +16.9% — 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.1% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -5.9% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +589.1% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
13
% held
0.4%
Net QoQ
+124.8K sh
Top holder
Garrett Wealth Advisory G…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
43.0K
Days to cover
1.0d
Change
+29.7K sh
View
Short Volume
Short vol %
54%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
932
Value
$3.6K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$128.5K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$596.8K
Net income (FY)
$-8.3M
EPS diluted
$-0.12
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 1, 2026
This year
10
View

Performance

5D 20D 120D MTD YTD
YDES +0.0% +100.9% +24.7% -4.2% -41.7%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -1.2% +100.3% +13.2% -5.8% -55.3%
Key facts CIK 2011674 CUSIP G98301107 13F (30d) 1 filings 1 filers Visit website Investor relations